Drug Profile
MB 101 - Mustang Bio
Alternative Names: Anti-IL13Rα2-CAR-4-1BB/BBzeta-CD19t-expressing T-cells; IL13(EQ)BBzeta/CD19t+ TCM-enriched T Cells; IL13Ralpha2-CAR T Cells; IL13Rα2 CAR T; IL13Rα2-specific CAR-T cells - Mustang Bio; IL13Rα2-targeted CAR T cell therapy; MB-101 - Mustang BioLatest Information Update: 12 Mar 2024
Price :
$50
*
At a glance
- Originator City of Hope National Medical Center
- Developer City of Hope National Medical Center; National Cancer Institute (USA)
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Brain cancer; Glioblastoma; Meningeal carcinomatosis
Most Recent Events
- 12 Mar 2024 MB 101 is in phase-I clinical trials in Brain cancer (Combination therapy, In children, In adults, In adolescents, Recurrent, Second-line therapy or greater) in USA (Intraventricular) (NCT04510051)
- 12 Mar 2024 MB 101 is still in phase I trial for Glioblastoma(Combination therapy, Monotherapy, Recurrent, Second-line therapy or greater) in USA (Intratumoural) (Intraventricualr) (NCT04003649) (Mustang Bio pipeline, March 2024)
- 12 Mar 2024 MB 101 is still in phase-I clinical trials in Meningeal carcinomatosis (Adjuvant therapy, Second-line therapy or greater) in USA (Intraventricular) (NCT04661384)